Alkermes Plc (Alkermes) conducts the research, development and commercialization of pharmaceutical products based on its scientific expertise and proprietary technologies to address the unmet medical needs of patients in major disease conditions. It has a diversified portfolio of marketed drugs and a clinical pipeline of products that address cancer, neurodegenerative and CNS disorders such as schizophrenia, multiple sclerosis (MS), depression and addiction.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing medicines for neurological conditions and cancer. Its major pipeline products include includes ALKS 2680 for Narcolepsy ; Olanzapine and samidorphan for Schizophrenia or Bipolar I Disorder; HDAC Inhibitors for Neurology or Neuropsychiatry; IL-12 and IL-18 for cancer; Nemvaleukin alfa for Mucosal Melanoma and Ovarian Cancer. The company develops its products based on its technology platforms. Its technology platforms include long-acting injectable technologies such as Medisorb, LinkeRx, NanoCrystal; Solid-Oral Dosage technology, NanOsmotic and Medifusion. The company has an R&D facility and corporate offices in Waltham, Massachusetts, the US; an R&D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio, the US. In FY2022, the company spent US$381.8 million on its R&D activities.